DNA Methylation Cancer Detection
Early Cancer Detection & Monitoring
Clinical Validation/Service LaunchActive
Key Facts
Indication
Early Cancer Detection & Monitoring
Phase
Clinical Validation/Service Launch
Status
Active
Company
About YD Bio
YD Bio is a diversified biotech company with a multi-platform strategy spanning diagnostics, therapeutics, and clinical trial services. Its core focus is on DNA methylation-based early cancer detection, developed in partnership with EG Biomed, and exosome-based regenerative therapies for ophthalmology, developed with 3D Global Biotech. The company is publicly listed on Nasdaq, leverages strategic partnerships for R&D and commercialization, and operates a revenue-generating clinical trial supply business that supports its development-stage pipeline.
View full company profile